Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
38 Results for "
PTK2
" in MedChemExpress (MCE) Product Catalog:
Products (38)
38 Results for "PTK2" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-P80460
Synonyms: FAK, FAK1, PTK2, Focal adhesion kinase 1, FADK 1, Focal adhesion kinase-related nonkinase, Protein phosphatase 1 regulatory subunit 71, Protein-tyrosine kinase 2, p125FAK, pp125FAK, FRNK, PPP1R71
1
1 Cited Publications
TL12-186 is a multi-kinase PROTAC degrader. TL12-186 recruits the CRBN E3 ubiquitin ligase to target and degrade a variety of distinct kinases, including FLT3, BTK, AURKA, PTK2B, and multiple cyclin-dependent kinases (CDKs). TL12-186 can be used in leukemia-related research [2] .
1
1 Cited Publications
BI-3663 is a highly selective PTK2/FAK PROTAC (DC50 = 30 nM) with a Cereblon E3 ligase ligand capable of degrading PTK2, with an IC50 value of 18 nM. BI-3663 is a PROTAC generated by linking the PTK2/FAK inhibitor BI-4464 (HY-124625) with a Pomalidomide (HY-10984) derivative via a linker. BI-3663 can induce PTK2 degradation at low nanomolar concentrations. BI-3663 has antitumor activity .
1
1 Cited Publications
Cat. No.: HY-P86571
Synonyms: PTK2; FAK; FAK1; Focal adhesion kinase 1; FADK 1; Focal adhesion kinase-related nonkinase; FRNK; Protein phosphatase 1 regulatory subunit 71; PPP1R71; Protein-tyrosine kinase 2; p125FAK; pp125FAK
BI-4464 is a highly selective, ATP competitive PTK2/FAK protein kinase inhibitor with an IC50 value of 17 nM. BI-4464 is a FAK (HY-43760) ligand and linker conjugate. BI-4464 can be used to construct proteolysis targeting chimeras (PROTACs), such as PROTAC FAK degrader 4 (HY-178467). PROTAC FAK degrader 4 is a highly potent and selective FAK PROTAC degrader [2] .
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
Target:
PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)
Research Areas:
DB1113 is a multi-kinase PROTAC degrader. DB1113 induces the ubiquitination and degradation of ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used to study diseases or disorders mediated by aberrant kinase activity .
Target:
PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK NEKs
Research Areas:
DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity [2].
Cat. No.: HY-RS11399
Target:
Research Areas:
PTK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PTK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11400
Target:
Research Areas:
Ptk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ptk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS11401
Target:
Research Areas:
Ptk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ptk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-176198
CAS No.: 2341740-85-8
BI-0319 is a potent and selective PTK2 (FAK) PROTAC degrader with an IC50 of 19 nM and a DC50 of 243 nM (in A549 cells). By bridging PTK2 and VHL E3 ubiquitin ligase, BI-0319 induces polyubiquitination of PTK2, leading to its targeted degradation via the ubiquitin-proteasome system. BI-0319 can be used in research related to liver cancer and non-small cell lung cancer .
Cat. No.: HY-130422
CAS No.: 217817-01-1
Synonyms: Tos-PEG4-Boc
Target:
Research Areas:
Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) is a PROTAC linker, which refers to the PEG composition. Tos-PEG4-t-butyl ester (Tos-PEG4-Boc) can be used in the synthesis of a series of PROTACs, such as BI-3663 (HY-111546). BI-3663 is a highly selective PTK2/FAK PROTAC, with cereblon ligands to hijack E3 ligases for PTK2 degradation, and inhibits PTK2 with an IC50 of 18 nM .
Cat. No.: HY-122844B
CAS No.: 2761021-80-9
Synonyms: BI-853520 tosylate; IN-10018 tosylate
Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor. Ifebemtinib (tosylate) demonstrates anti-tumor activity. Ifebemtinib (tosylate) inhibits FAK autophosphorylation in prostate carcinoma cells. Ifebemtinib (tosylate) can inhibit spheroid formation and orthotopic tumor growth in vivo. Ifebemtinib (tosylate) can be studied in anticancer research such as solid tumors, breast cancer, and malignant pleural mesothelioma [2] .
Cat. No.: HY-111546R
CAS No.: 2341740-84-7
Target:
Research Areas:
BI-3663 (Standard) is the analytical standard of BI-3663 (HY-111546). This product is intended for research and analytical applications. BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker . Anti-cancer activity .
Cat. No.: HY-RS11402
Target:
Research Areas:
PTK2B Human Pre-designed siRNA Set A contains three designed siRNAs for PTK2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS20473
Target:
Research Areas:
Ptk2b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ptk2b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P85584
Synonyms: FADK 1; FADK; FAK 1; FAK 1; FAK related non kinase polypeptide; FAK1; FAK1_HUMAN; Focal adhesion kinase 1; Focal adhesion kinase 1; Focal adhesion Kinase; Focal adhesion kinase isoform FAK Del33; Focal adhesion kinase related nonkinase; FRNK; p125FAK; pp125FAK; pp125FAK; PPP1R71; Protein phosphatase 1 regulatory subunit 71; Protein tyrosine kinase 2; Protein Tyrosine Kinase Cytoplasmic; Protein Tyrosine Kinase Cytoplasmic; Protein-tyrosine kinase 2; PTK 2; PTK 2; PTK2; PTK2 protein tyrosine kinase 2; PTK2 protein tyrosine kinase 2.
Cat. No.: HY-P701682
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: PTK2; Protein Phosphatase 1 Regulatory Subunit 71; Protein Tyrosine Kinase 2; PTK2 Protein Tyrosine Kinase 2; PPP1R71; Protein-Tyrosine Kinase 2; FAK1; FADK 1; FAK; FRNK; Focal Adhesion Kinase-Related Nonkinase; CDNA FLJ57218, Highly Similar To Focal Adhe
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P706087
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: PTK2; Protein Phosphatase 1 Regulatory Subunit 71; Protein Tyrosine Kinase 2; PTK2 Protein Tyrosine Kinase 2; PPP1R71; Protein-Tyrosine Kinase 2; FAK1; FADK 1; FAK; FRNK; Focal Adhesion Kinase-Related Nonkinase; CDNA FLJ57218, Highly Similar To Focal Adhe
Species:
Human
Source:
Sf9 insect cells
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
